Synexa Life Sciences
Claire Jenkins is the Chief Commercial Officer at Synexa Life Sciences, a position held since August 2022, where Claire leads efforts in providing innovative biomarker and bioanalytical services. Prior to this role, Claire served as Senior Director and Head of EMEA Business Development at Q2 Solutions from September 2014 to May 2022. Claire's career spans various leadership positions including Commercial Director at Arrayjet Ltd, Director at Ravendean Ventures, and Sales & Marketing Director at Biopta Ltd, among others. Claire began a career in sales and technical roles at companies including Quintiles, PerkinElmer, Anachem, and Procter & Gamble after earning a BSc Hons in Applied Chemistry from Northumbria University in 1995.
This person is not in any offices
Synexa Life Sciences
Synexa Life Sciences is a global provider of biomarker and bioanalytical services, specialising in the development, validation, and delivery of a wide range of complex and custom-designed assays. With a team of 150 across five global laboratory locations; Cape Town, London, Berlin, Turku (Finland) and Rockville (Maryland USA), we provide innovative solutions to support our customers to achieve their clinical milestones. Our main areas of expertise include biomarker identification and development, clinical bioanalysis, soluble biomarker analysis (utilising MSD, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry and ELISpot) and genomic services to support clinical trials and translational studies. We pride ourselves on our deep scientific expertise and our ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis. We partner with our customers to contribute to the furtherment of scientific development and ultimately better management and treatment of human health. Synexa, improving the quality of human health through innovative biomarker and bioanalytical solutions.